These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 17805032)

  • 1. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
    Christoforidis A; Zevgaridou E; Tsatra I; Perifanis V; Vlachaki E; Papassotiriou I; Apostolakou F; Athanassiou-Metaxa M
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):598-601. PubMed ID: 17805032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N
    Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E; Canatan D; Ormeci AR; Vural H; Aylak F
    J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Br J Haematol; 2009 Apr; 145(2):245-54. PubMed ID: 19236376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
    Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
    J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy with deferoxamine and deferiprone.
    Kattamis A
    Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
    Christoforidis A; Haritandi A; Tsatra I; Tsitourides I; Karyda S; Athanassiou-Metaxa M
    Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.
    Christoforidis A; Perifanis V; Tsatra I; Vlachaki E; Athanassiou-Metaxa M
    Diabetes Res Clin Pract; 2007 Apr; 76(1):6-11. PubMed ID: 16930760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V; Bourantas D; Chaidos A; Bouranta P; Gouva M; Vassou A; Tzouvara E; Bourantas KL
    Hematol J; 2004; 5(6):475-9. PubMed ID: 15570288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.